Albany, NY -- (SBWIRE) -- 03/20/2020 -- Ataxia Telangiectasia Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Ataxia Telangiectasia Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. Ataxia Telangiectasia occurs in 1 in 40,000–100,000 people worldwide.
2. Males and females are affected in equal numbers. In the United States, the prevalence is approximately 1 in 40,000–100,000 live births.
3. In the United States, about one per cent of the population is a carrier of a mutation in the Ataxia Telangiectasia mutated kinase (ATM) gene.
4. The average Ataxia Telangiectasia prevalence is 1 per 100,000 children. The most reliable estimates for the number of people with Ataxia Telangiectasia, in the UK at least are 3 per million.

Key benefits of the report
1. Ataxia Telangiectasia market report covers a descriptive overview and comprehensive insight of the Ataxia Telangiectasia epidemiology and Ataxia Telangiectasia market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Ataxia Telangiectasia market report provides insights on the current and emerging therapies.
3. Ataxia Telangiectasia market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Ataxia Telangiectasia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Ataxia Telangiectasia market.

Request for sample pages

"Ataxia Telangiectasia patients have about a 10% risk of developing lymphoma or leukaemia."

Ataxia Telangiectasia is a complex genetic neurodegenerative disorder that affects during infancy or early childhood. The disorder is responsible for impaired coordination of voluntary movements.

Currently, there is no approved drug therapy or cure for Ataxia Telangiectasia treatment. The available treatment approaches are symptomatic and supportive in nature. Therapeutic drugs being used in the treatment of Ataxia Telangiectasia includes antibiotics, vaccines (Streptococcus pneumonia, Neisseria meningitides, Hemophilus influenza), Immunoglobulin, Neuroprotective Treatments (Antioxidants (vitamin E or a-lipoic acid)), Antiepileptic drugs and Glucocorticoids. Physical and occupational therapies help to maintain flexibility. Speech therapy is recommended to control airflow to the vocal cords. Gamma-globulin injections may be useful if immunoglobulin levels are sufficiently reduced to weaken the immune system.

Antioxidants, such as Vitamin E or A-lipoic acid, are prescribed to some patients, although there has been no formal testing for the efficacy in Ataxia Telangiectasia affected individuals. Prophylactic antibiotics are prescribed for patients with recurrent infection, but this is done blindly in most cases since microbiological evaluation did not take place, and there is the added risk of bacterial resistance development. Antiepileptic drugs, such as Pregabalin and Tiagabine, have seen to improve the patient's gait in a few cases. Glucocorticoids have been found to be useful in the Ataxia Telangiectasia treatment of neurometabolic and neurogenetic manifestations.

Even though various therapeutic approaches are available, but these therapies provide only symptomatic relief, overuse of Glucocorticoids may cause severe adverse effects, radiation therapy used in diagnosis may cause hypersensitivity. Even the diagnosis of Ataxia Telangiectasia is questionable when accompanied by severe mental retardation, seizures, nonprogressive ataxia, or microcephaly. The most common misdiagnosis is cerebral palsy. So, all these limitations create an urgent demand for more advanced diagnostic methods to overcome misdiagnosis and novel therapies to treat the root cause of Ataxia Telangiectasia.

Overall, the Ataxia Telangiectasia therapeutics market is further expected to increase by the major drivers, such as rising prevalent population, technological advancements, and upcoming therapies in the forecast period [2020–2030].

The launch of the emerging therapies is expected to significantly impact Ataxia Telangiectasia treatment scenario in the upcoming years:-
Drugs covered
1. EryDex System
2. IB1001
And many others

The key players in Ataxia Telangiectasia market are:
1. EryDel
2. IntraBio
And many others

Table of contents
1. Report Introduction
2. Ataxia Telangiectasia Market Overview at a Glance
3. Ataxia Telangiectasia Executive Summary
4. Ataxia Telangiectasia SWOT
5. Ataxia Telangiectasia Disease Background and Overview
6. Ataxia Telangiectasia Epidemiology and Patient Population
6.1. Assumptions and Rationale
6.2. 7MM Prevalent cases of Ataxia Telangiectasia (2017–2030)
6.3. Diagnosed Cases of Ataxia Telangiectasia (2017–2030)
6.4. Treatable Cases of Ataxia Telangiectasia (2017–2030)
6.5. Ataxia Telangiectasia Country- Wise Epidemiology
6.6. United States
6.7. EU-5
6.8. Assumptions and Rationale
6.9. Germany
6.10. France
6.11. Italy
6.12. Spain
6.13. United Kingdom
6.14. Japan
7. Ataxia Telangiectasia Current Therapies
8. Ataxia Telangiectasia Emerging Therapies
9. Key Cross Competition
9.1. EryDex System: EryDel
9.2. IB1001: IntraBio
10. Ataxia Telangiectasia Market Size
11. 7MM Ataxia Telangiectasia Country-Wise Market Analysis
12. United States Market Size
13. Germany Market Size
14. France Market Size
15. United Kingdom Market Size
16. Spain Market Size
17. Italy Market Size
18. Japan Market Size
19. Market Drivers
20. Market Barriers
21. Ataxia Telangiectasia Report Methodology
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.